This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Glesatinib
- DrugBank Accession Number
- DB06302
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Glesatinib (DB06302)
- Weight
- Average: 619.71
Monoisotopic: 619.152338423 - Chemical Formula
- C31H27F2N5O3S2
- Synonyms
- Glesatinib
- External IDs
- MG-90265
- MG-90265X
- MG90265
- MG90265X
- MGCD-265
- MGCD265
Pharmacology
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Glesatinib. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Glesatinib. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Glesatinib. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Glesatinib. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Glesatinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Glesatinib. Methimazole The therapeutic efficacy of Methimazole can be decreased when used in combination with Glesatinib. Parathyroid hormone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Glesatinib. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Glesatinib. Potassium perchlorate The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Glesatinib. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7Q29OXD98N
- CAS number
- 936694-12-1
- InChI Key
- YRCHYHRCBXNYNU-UHFFFAOYSA-N
- InChI
- InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42)
- IUPAC Name
- 3-(3-fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)-1-[2-(4-fluorophenyl)acetyl]thiourea
- SMILES
- COCCNCC1=CC=C(N=C1)C1=CC2=NC=CC(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=C2S1
References
- General References
- Not Available
- External Links
- ChemSpider
- 52084900
- ChEMBL
- CHEMBL3989914
- ZINC
- ZINC000113139653
- Wikipedia
- Glesatinib
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Non-Small Cell Lung Cancer (NSCLC) 1 2 Completed Treatment Non-Small Cell Lung Carcinoma 1 1 Completed Treatment Advanced Malignant Neoplasm 3 1 Terminated Treatment Advanced Malignancies, Non-small Cell Lung Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 8.1e-05 mg/mL ALOGPS logP 5.42 ALOGPS logP 5.46 Chemaxon logS -6.9 ALOGPS pKa (Strongest Acidic) 9.27 Chemaxon pKa (Strongest Basic) 8.28 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 97.4 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 166.04 m3·mol-1 Chemaxon Polarizability 63.77 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at March 19, 2008 16:23 / Updated at February 21, 2021 18:52